Advanced Biological Laboratories (ABL) announced today that DeepChek®
and ViroScore® Suite clinical genotyping solutions are now CE-IVD (In
Vitro Diagnostics) approved for commercial use in Europe and other
countries that recognise CE certification.
This approval is further validating the use of our next generation
sequencing (NGS) downstream analysis software DeepChek®-HIV with several
evaluations performed by renowned clinical and virological research
centres and the positive results from several international scientific
studies. Scientific results from these studies will be presented at
upcoming scientific conferences, including the International Workshop on
Drug Resistance for HIV and Viral Hepatitis, to be held in Sitges
(Spain, 5-9 June, 2012).
"Scientific experts worldwide are increasingly recognising our IT
solutions dedicated to HIV clinical genotyping analysis, namely Sanger
sequencing within our ViroScore® Suite system and NGS within our
DeepChek® system. The CE-IVD approval is in compliance with the latest
European directives for medical devices, and positions DeepChek® and
ViroScore® Suite as the first IT solutions choices to analyse
comprehensive and complex data, thereby pioneering optimised
personalised for the treatment of HIV", stated Dr. Chalom B. Sayada, CEO
of ABL. "It's also a monumental milestone in our portfolio of medical IT
solutions, wherein other growing IVD-segments, such as viral hepatitis,
oncology and other chronic diseases, are also being targeted by ABL."
Advanced Biological Laboratories